![]()
|
|
||||||||
J. Biol. Chem., Vol. 280, Issue 18, 17694-17700, May 6, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






¶
||
From the
Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka 812-8582,
CREST, the Japan Science and Technology Corporation, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, and the ¶Department of Developmental Biology, Center for Translational and Advanced Animal Research on Human Disease, Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan
The cyclin-dependent kinase (CDK) inhibitor p27 is degraded at the G0-G1 transition of the cell cycle by the ubiquitin-proteasome pathway in a Skp2-independent manner. We recently identified a novel ubiquitin ligase, KPC (Kip1 ubiquitylation-promoting complex), consisting of KPC1 and KPC2, which regulates the ubiquitin-dependent degradation of p27 at G1 phase. We have now investigated the structural requirements for the interactions of KPC1 with KPC2 and p27. The NH2-terminal region of KPC1 was found to be responsible for binding to KPC2 and to p27. KPC1 mutants that lack this region failed to mediate polyubiquitylation of p27 in vitro and expression of one such mutant delayed p27 degradation in vivo. We also generated a series of deletion mutants of p27 and found that KPC failed to polyubiquitylate a p27 mutant that lacks the CDK inhibitory domain. Interestingly, the cyclin E·CDK2 complex prevented both the interaction of KPC with p27 as well as KPC-mediated polyubiquitylation of p27. A complex of cyclin E with a kinase-negative mutant of CDK2 also exhibited these inhibitory effects, suggesting that cyclin E·CDK2 competes with KPC1 for access to the CDK inhibitory domain of p27. These results suggest that free p27 is recognized by the NH2-terminal region of KPC1, which also associates with KPC2, and that p27 is then polyubiquitylated by the COOH-terminal RING-finger domain of KPC1.
Received for publication, January 24, 2005 , and in revised form, March 2, 2005.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
|| To whom correspondence should be addressed. Tel.: 81-92-642-6815; Fax: 81-92-642-6819; E-mail: nakayak1{at}bioreg.kyushu-u.ac.jp.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
F. Felicetti, M. C. Errico, L. Bottero, P. Segnalini, A. Stoppacciaro, M. Biffoni, N. Felli, G. Mattia, M. Petrini, M. P. Colombo, et al. The Promyelocytic Leukemia Zinc Finger-MicroRNA-221/-222 Pathway Controls Melanoma Progression through Multiple Oncogenic Mechanisms Cancer Res., April 15, 2008; 68(8): 2745 - 2754. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Petrovic, R. H. Costa, L. F. Lau, P. Raychaudhuri, and A. L. Tyner FoxM1 Regulates Growth Factor-induced Expression of Kinase-interacting Stathmin (KIS) to Promote Cell Cycle Progression J. Biol. Chem., January 4, 2008; 283(1): 453 - 460. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Susaki, K. Nakayama, and K. I. Nakayama Cyclin D2 Translocates p27 out of the Nucleus and Promotes Its Degradation at the G0-G1 Transition Mol. Cell. Biol., July 1, 2007; 27(13): 4626 - 4640. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lecanda, T. V. Parekh, P. Gama, K. Lin, V. Liarski, S. Uretsky, K. Mittal, and L. I. Gold Transforming Growth Factor-{beta}, Estrogen, and Progesterone Converge on the Regulation of p27Kip1 in the Normal and Malignant Endometrium Cancer Res., February 1, 2007; 67(3): 1007 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Kouvaraki, A. L. Korapati, G. Z. Rassidakis, L. Tian, Q. Zhang, P. Chiao, L. Ho, D. B. Evans, and F. X. Claret Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma. Cancer Res., September 1, 2006; 66(17): 8581 - 8589. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Halfter, M. Friedrich, A. Resch, M. Kullmann, F. Stogbauer, E. B. Ringelstein, and L. Hengst Oncostatin M Induces Growth Arrest by Inhibition of Skp2, Cks1, and Cyclin A Expression and Induced p21 Expression. Cancer Res., July 1, 2006; 66(13): 6530 - 6539. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Borriello, V. Cucciolla, M. Criscuolo, S. Indaco, A. Oliva, A. Giovane, D. Bencivenga, A. Iolascon, V. Zappia, and F. Della Ragione Retinoic Acid Induces p27Kip1 Nuclear Accumulation by Modulating Its Phosphorylation. Cancer Res., April 15, 2006; 66(8): 4240 - 4248. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Q. Li, Q. Jiang, E. Aleem, P. Kaldis, A. R. Khaled, and S. K. Durum IL-7 promotes T cell proliferation through destabilization of p27Kip1 J. Exp. Med., March 20, 2006; 203(3): 573 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Besson, M. Gurian-West, X. Chen, K. S. Kelly-Spratt, C. J. Kemp, and J. M. Roberts A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression Genes & Dev., January 1, 2006; 20(1): 47 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hara, T. Kamura, S. Kotoshiba, H. Takahashi, K. Fujiwara, I. Onoyama, M. Shirakawa, N. Mizushima, and K. I. Nakayama Role of the UBL-UBA Protein KPC2 in Degradation of p27 at G1 Phase of the Cell Cycle Mol. Cell. Biol., November 1, 2005; 25(21): 9292 - 9303. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |